Phagepro, P.b.c.
Somerville, MA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 103 Hillsdale Rd, West Somerville, MA 02144, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Locus Biosciences Inc. | Morrisville, NC | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Vulcan Biologics Inc. | — | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Intralytix Inc. | Columbia, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Curza Inc. | Salt Lake City, UT | — |
| Aimmax Therapeutics Inc. | Durham, NC | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Phagepro, P.b.c., doing business as Phagepro Inc., is a minority-owned, woman-owned small business registered in SAM.gov since February 22, 2017, with a registration valid through June 17, 2025. The company is structured as a for-profit corporate entity focused on developing innovative bacteriophage-based solutions for infectious disease prevention and treatment. Specifically, Phagepro specializes in research and development of phage cocktails targeting bacterial infections, with a primary focus on addressing cholera and antibiotic-resistant bacterial strains.
The company has received multiple federal grant awards from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). These grants have supported critical research initiatives, including a $1,000,000 project grant to develop a prophylactic cholera phage cocktail with a project period from December 16, 2024, to May 31, 2027, and a $173,300 grant to prepare for a Phase I/II clinical trial of their Prophylactic-VC™ (PVC) product. Another notable grant focused on targeting antibiotic resistance genes in Vibrio cholerae using a phage-encoded CRISPR-Cas system. The research aims to develop innovative approaches to prevent cholera transmission, particularly in regions with high cholera risk, by creating targeted phage interventions that can potentially reduce infection rates and combat multidrug-resistant bacterial strains. Phagepro's work involves extensive collaboration with research institutions, including the International Centre for Diarrhoeal Diseases Research in Bangladesh, to advance their groundbreaking infectious disease prevention strategies.
Quick answers
Is Phagepro, P.b.c. registered in SAM.gov?
Yes. Phagepro, P.b.c.'s SAM.gov registration is active through May 22, 2027.
What is Phagepro, P.b.c.'s CAGE code?
Phagepro, P.b.c.'s CAGE code is 7TC00, and its Unique Entity ID (UEI) is KHNEFNHKMN84.
What is Phagepro, P.b.c.'s most recent federal award?
Phagepro, P.b.c.'s most recent federal grant award is Manufacturing and formulation process development for a prophylactic cholera phage cocktail (R44AI188855), from National Institute of Allergy and Infectious Diseases (NIH), on December 16, 2024.
On GovTribe
See Phagepro, P.b.c.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors